TWIST1 and bladder transitional cell carcinoma: Overall, our study suggests that the methylation status of the TWIST1/Vimentin promoter, functioning as urinary methylation markers, provides a valuable noninvasive strategy for the sensitive and specific identification of bladder urothelial carcinoma (BUC), achieving a sensitivity of 73% and a specificity of 83%.